The longer life your patients with mCSPC or nmCRPC want may still be possible—with ERLEADA®

OS icon
safety icon
PSA icon
HRQoL icon

*Patients receiving ERLEADA® should also receive a GnRH analog concurrently or should have had bilateral orchiectomy.1

†ERLEADA® is a second-generation androgen receptor inhibitor.1

ADT = androgen deprivation therapy; CI = confidence interval; GnRH = gonadotropin-releasing hormone; HR = hazard ratio; HRQoL = health-related quality of life; mCSPC = metastatic castration-sensitive prostate cancer; NE = not estimable; nmCRPC = non-metastatic castration-resistant prostate cancer; OS = overall survival; PSA = prostate-specific antigen.

YOUR PATIENT’S TREATMENT JOURNEY STARTS HERE

  • Financial Assistance: Education and resources that may be able to help your patients save on potential out-of-pocket medication costs

  • Medication & Disease Education: Help patients gain a better understanding of their disease, their current treatment, and how to have meaningful conversations with loved ones and their care team during upcoming visits

  • Practical Needs & General Well-Being: Learn lifestyle and coping skills to help manage stress and get connected to the resources your patients need, including support groups and transportation assistance

Learn more

REFERENCES:

  1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. Nubeqa® [Prescribing Information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.
  3. Xtandi® [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc.
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 17, 2024. To view the most recent and complete version of the guideline, go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  5. Chi KN, Chowdhury S, Bjartell A, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294-2303.
  6. A study of apalutamide (JNJ-56021927, ARN-509) plus androgen deprivation therapy (ADT) versus ADT in participants with mCSPC (TITAN). ClinicalTrials.gov identifier: NCT02489318. Updated February 15, 2023. Accessed May 22, 2024. https://clinicaltrials.gov/ct2/show/NCT02489318?term=apalutamide&cond=prostate+cancer&draw=4&rank=22